Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Aug 26;17(1):327.
doi: 10.1186/s13023-022-02463-x.

Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study

Bruce Wang  1 , Paolo Ventura  2 , Kei-Ichiro Takase  3 , Manish Thapar  4 , David Cassiman  5 , Ilja Kubisch  6 , Shangbin Liu  7 , Marianne T Sweetser  7 , Manisha Balwani  8
Affiliations
Clinical Trial

Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study

Bruce Wang et al. Orphanet J Rare Dis. .

Abstract

Background: Acute hepatic porphyria (AHP) is a family of four rare genetic diseases, each involving deficiency in a hepatic heme biosynthetic enzyme. Resultant overproduction of the neurotoxic intermediates δ-aminolevulinic acid (ALA) and porphobilinogen (PBG) leads to disabling acute neurovisceral attacks and progressive neuropathy. We evaluated the AHP disease burden in patients aged ≥ 12 years in a post hoc analysis of the Phase 3, randomized, double-blind, placebo-controlled ENVISION trial of givosiran (NCT03338816), an RNA interference (RNAi) therapeutic that targets the enzyme ALAS1 to decrease ALA and PBG production. We analyzed baseline AHP severity via chronic symptoms between attacks, comorbidities, concomitant medications, hemin-associated complications, and quality of life (QOL) and evaluated givosiran (2.5 mg/kg monthly) in patients with and without prior hemin prophylaxis on number and severity of attacks and pain scores during and between attacks.

Results: Participants (placebo, n = 46; givosiran, n = 48) included patients with low and high annualized attack rates (AARs; range 0-46). At baseline, patients reported chronic symptoms (52%), including nausea, fatigue, and pain; comorbidities, including neuropathy (38%) and psychiatric disorders (47%); concomitant medications, including chronic opioids (29%); hemin-associated complications (eg, iron overload); and poor QOL (low SF-12 and EuroQol visual analog scale scores). A linear relationship between time since diagnosis and AAR with placebo suggested worsening of disease over time without effective treatment. Givosiran reduced the number and severity of attacks, days with worst pain scores above baseline, and opioid use versus placebo.

Conclusions: Patients with AHP, regardless of annualized attack rates, have considerable disease burden that may partly be alleviated with givosiran.

Keywords: Acute hepatic porphyria; Chronic symptoms; Disease burden; Givosiran; Porphyria attack; Quality of life.

PubMed Disclaimer

Conflict of interest statement

Bruce Wang reports being a scientific advisor to Alnylam Pharmaceuticals and Recordati Rare Diseases. Paolo Ventura reports receiving advisory board fees and lecture fees from Alnylam Pharmaceuticals and advisory board fees from Recordati Rare Diseases. Kei-ichiro Takase reports having nothing to disclose. Manish Thapar reports being a consultant and speaker for Alnylam. David Cassiman and the University of Leuven, University Hospital Leuven report receiving research grants, travel and conference bursaries, speaker fees, and advisory board compensation from a.o. Sanofi-Genzyme, Takeda-Shire, Alexion, Alnylam, BioMarin, Actelion, Bayer, Roche, BMS, Schering-Plough, Synageva, and Chiesi. Ilja Kubisch reports receiving fees from Alnylam. Shangbin Liu reports being an employee of and owning stock and stock options in Alnylam. Marianne T. Sweetser reports being an employee of and owning stock and stock options in Alnylam. Manisha Balwani reports receiving grant support, consulting fees, advisory board fees, and lecture fees from Alnylam Pharmaceuticals, advisory board fees from Recordati Rare Diseases, grant support and advisory board fees from Mitsubishi Tanabe, and advisory board fees from Alexion, Genzyme/Sanofi, and Takeda. In addition, Mount Sinai faculty are named co-inventors with Alnylam on a patent related to the development of givosiran, the study drug. The Icahn School of Medicine at Mount Sinai receives payments related to this patent from Alnylam, and a portion of these payments are also distributed to faculty and other co-inventors.

Figures

Fig. 1
Fig. 1
Comorbidities in ENVISION trial participants at baseline
Fig. 2
Fig. 2
Complications and comorbidities in ENVISION trial participants according to hemin prophylaxis at baseline
Fig. 3
Fig. 3
Association between years since diagnosis of AHP and mean historical annualized attack rate during ENVISION trial
Fig. 4
Fig. 4
Attack frequency (A), proportion of attack-free patients by 3-month interval (B), and hemin use (C) with long-term givosiran treatment in patients with or without prior hemin prophylaxis usea. aHemin prophylaxis was not allowed during the study; days of hemin use therefore refers only to hemin used to treat attacks
Fig. 5
Fig. 5
Proportions of patients with ≥ 1 attack at Month 6 in ENVISION trial according to hemin prophylaxis at baseline
Fig. 6
Fig. 6
Daily worst pain scores during attack-free periods in ENVISION trial
Fig. 7
Fig. 7
Proportion of days with opioid use in patients with or without prior hemin prophylaxis use. aAnalgesic use was collected in an electronic diary up to Month 12
Fig. 8
Fig. 8
Mean change from baseline in SF-12 PCS scores in patients with or without prior hemin prophylaxis use. Higher scores represent improvement in that summary or domain
See this image and copyright information in PMC

References

    1. Ramanujam VM, Anderson KE. Porphyria diagnostics-part 1: a brief overview of the porphyrias. Curr Protoc Hum Genet. 2015;86:17.20.1–17.20.6. - PMC - PubMed
    1. Anderson KE, Bloomer JR, Bonkovsky HL, Kushner JP, Pierach CA, Pimstone NR, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med. 2005;142(6):439–450. doi: 10.7326/0003-4819-142-6-200503150-00010. - DOI - PubMed
    1. Peoc'h K, Manceau H, Karim Z, Wahlin S, Gouya L, Puy H, et al. Hepatocellular carcinoma in acute hepatic porphyrias: a Damocles sword. Mol Genet Metab. 2019;128(3):236–241. doi: 10.1016/j.ymgme.2018.10.001. - DOI - PubMed
    1. Pallet N, Karras A, Thervet E, Gouya L, Karim Z, Puy H. Porphyria and kidney diseases. Clin Kidney J. 2018;11(2):191–197. doi: 10.1093/ckj/sfx146. - DOI - PMC - PubMed
    1. Bissell DM, Wang B. Acute hepatic porphyria. J Clin Transl Hepatol. 2015;3(1):17–26. doi: 10.14218/JCTH.2014.00039. - DOI - PMC - PubMed

Publication types

Supplementary concepts

Associated data